Abstract
Since the initial identification of microRNAs (miRNA) in C. elegans, functional characterisation of these small non-coding RNAs has demonstrated their critical involvement in numerous biological processes. Typically 20-22 nucleotides in length, miRNAs act as negative gene regulators at the post-transcriptional level. A large body of evidence points to the role of miRNAs in haematopoiesis. miRNAs provide a network of signals important for haematopoietic cell maintenance, lineage differentiation and cell maturation. The mechanism by which they mediate their effects in haematopoiesis is complex, demonstrating cell-specific, tissue-specific and maturation-specific expression. Understanding haematopoietic expression and key targets of miRNAs is important to further elucidate the functional roles of miRNAs. Furthermore, an appreciation of their role in normal physiological processes sheds light on the possibility that aberrations of miRNA expression may perturb these processes and cause disease. Indeed, deregulation of miRNAs has been demonstrated in oncogenesis and in haematological malignancies in particular. This review focuses on miRNA expression in normal haematopoiesis and provides brief insight into how deregulation of these miRNA may contribute to cancer pathogenesis.
Keywords: miRNA, haematopoiesis, cancer, DiGeorge Syndrome, double-stranded RNA
Current Signal Transduction Therapy
Title:MicroRNAs - Key Players in Haematopoiesis
Volume: 8 Issue: 1
Author(s): Stephanie Gounaris-Shannon, Sarah Newbury and Timothy Chevassut
Affiliation:
Keywords: miRNA, haematopoiesis, cancer, DiGeorge Syndrome, double-stranded RNA
Abstract: Since the initial identification of microRNAs (miRNA) in C. elegans, functional characterisation of these small non-coding RNAs has demonstrated their critical involvement in numerous biological processes. Typically 20-22 nucleotides in length, miRNAs act as negative gene regulators at the post-transcriptional level. A large body of evidence points to the role of miRNAs in haematopoiesis. miRNAs provide a network of signals important for haematopoietic cell maintenance, lineage differentiation and cell maturation. The mechanism by which they mediate their effects in haematopoiesis is complex, demonstrating cell-specific, tissue-specific and maturation-specific expression. Understanding haematopoietic expression and key targets of miRNAs is important to further elucidate the functional roles of miRNAs. Furthermore, an appreciation of their role in normal physiological processes sheds light on the possibility that aberrations of miRNA expression may perturb these processes and cause disease. Indeed, deregulation of miRNAs has been demonstrated in oncogenesis and in haematological malignancies in particular. This review focuses on miRNA expression in normal haematopoiesis and provides brief insight into how deregulation of these miRNA may contribute to cancer pathogenesis.
Export Options
About this article
Cite this article as:
Gounaris-Shannon Stephanie, Newbury Sarah and Chevassut Timothy, MicroRNAs - Key Players in Haematopoiesis, Current Signal Transduction Therapy 2013; 8 (1) . https://dx.doi.org/10.2174/1574362411308010012
DOI https://dx.doi.org/10.2174/1574362411308010012 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Overview of Innovations in Analysis and Beneficial Health Effects of Wine Polyphenols
Mini-Reviews in Medicinal Chemistry Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy
Current Medicinal Chemistry <i>Anastatica hierochuntica </i>Extracts: Promising, Safe and Selective Anticancer Agents
The Natural Products Journal Dendritoma Vaccine for Cancer: A Hopeful Approach
Current Cancer Therapy Reviews Accessing Cancer Metabolic Pathways by the Use of Microarray Technology
Current Pharmaceutical Design Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design N6-Isopentenyladenosine and its Analogue N6-Benzyladenosine Induce Cell Cycle Arrest and Apoptosis in Bladder Carcinoma T24 Cells
Anti-Cancer Agents in Medicinal Chemistry α(N)-Heterocyclic Thiosemicarbazones: Iron Chelators that are Promising for Revival of Gallium in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design The Role of AMPK/mTOR Modulators in the Therapy of Acute Myeloid Leukemia
Current Medicinal Chemistry Nutrition Support of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Current Nutrition & Food Science Different Aspects of Head and Neck Squamous Cell Carcinoma: Cancer Stem Cells, their Niche and Targeted Therapy
Current Stem Cell Research & Therapy Cancer Stem Cells – Are Surface Markers Alone Sufficient?
Current Stem Cell Research & Therapy The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets HLA Peptide-mediated Strategies for Modulation of Cellular and Humoral Immune Response in Transplantation
Current Pharmacogenomics Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Cell Death Targeting Therapies in B Lymphoid Malignancies
Current Drug Targets The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics New Medical Strategies for Midgut Carcinoids
Anti-Cancer Agents in Medicinal Chemistry